AIM · AIM ImmunoTech Inc.

📣 What AIM Says Is Next

• Q1 2027 · Ampligen: “We anticipate DURIPANC data on clinical benefit in Q1 2027 and on Overall Survival – the gold standard data point in oncology – in Q3 2027.”
  Company press release, Aug 10, 2026 · SEC filing
• this year · “Erasmus MC expects that detailed data will be published later this year.”
  Company press release, Feb 5, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

🧪 Trial & FDA Catalysts

• Nov 2023 · Phase 2 · Results Expected · Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditio
  Registry primary completion date, not a results date
• Aug 2006 · Phase 2 · Results Expected · The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART
  Registry primary completion date, not a results date
• Apr 2006 · Phase 2 · Results Expected · Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers
  Registry primary completion date, not a results date
• Feb 2004 · Phase 3 · Results Expected · The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome
  Registry primary completion date, not a results date

📊 Drug Pipeline

Also used in these trials (approved or third-party drugs, not AIM's own candidates): Pembrolizumab, Paclitaxel, Durvalumab, Cisplatin, Celecoxib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AIM holds $10M in cash and short-term investments (as of Jun 30, 2026) and burns about $3.7M/quarter from operations, an estimated runway of 8.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 60 · High

• Cash runway 8 months +30
• ATM program on file since May 2026 +15
• Shelf registration (S-3, Apr 2025) +10
• Going-concern doubt in the latest 10-Q +15The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or ev 10-Q, Aug 2026
• Raised after last reported balance sheet (Sep 2026) -10

Recent financing filings on SEC EDGAR:

• Sep 14, 2026 · Private placement (8-K Item 3.02) · 8-K
• Sep 10, 2026 · Private placement (8-K Item 3.02) · 8-K
• Sep 4, 2026 · Private placement (8-K Item 3.02) · 8-K
• Jun 11, 2026 · Private placement (8-K Item 3.02) · 8-K
• Jun 10, 2026 · Registered direct / best-efforts offering, $1M · 424B5
• May 21, 2026 · Registered direct / best-efforts offering, $2M · 424B5

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AIM files for a raise →

👥 Who Owns AIM

Share count 30,442,139 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.